The tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid (DMXAA) causes dramatic haemorrhagic necrosis in murine tumours, but activity is seen only at doses close to the toxic limit. This study investigates two approaches for increasing the therapeutic ratio of DMXAA. The first approach combines DMXAA with a second tumour blood flow inhibitor, 5-hydroxytryptamine (5-HT). Co-administration of 5-HT (700,mol kg-1) to C3H mice caused marked enhancement of DMXAA effects against MDAH-MCa-4 tumours, with dose-modifying factors (DMFs) of >3 for blood flow inhibition (at 4 h), 2.3 for necrosis (at 12 h) and 2.0 for growth delay, without compromising the maximum tolerated dose of DMXAA (90 gmol kg-'). The data are consistent with ischaemic injury to the tumour being the major mechanism of antitumour activity. The second approach combines DMXAA (± 5-HT) with hypoxia-selective bioreductive drugs. Anti-tumour activity of all three bioreductive drugs tested (tirapazamine, Cl-1010, SN 23816) was strongly potentiated by DMXAA, suggesting that there is a population of reversibly hypoxic tumour cells after DMXAA treatment. Co-administration of 5-HT further potentiated anti-tumour activity, but also increased host toxicity of tirapazamine and Cl-101 0 so that little therapeutic benefit was achieved. In contrast, the host toxicity of the dinitrobenzamide mustard SN 23816 was only slightly increased by DMXAAI5-HT, whereas the tumour growth delay at the maximum tolerated dose of SN 23816 was increased from 3.5 to 26.5 days. This study demonstrates that 5-HT and/or bioreductive drugs can improve the therapeutic activity of DMXAA in mice, and that with SN 23816 both approaches can be used together to provide considerably enhanced anti-tumour activity.
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent analogue of flavone-8-acetic acid (FAA), is currently in phase I clinical trial as an anti-cancer agent. Like FAA, DMXAA causes protracted inhibition of blood flow in murine tumours (Cliffe et al, 1994; Zwi et al, 1994a) leading to extensive haemorrhagic necrosis (Rewcastle et al, 1991; Zwi et al, 1994b) . The mechanism of blood flow inhibition is not fully understood, but DMXAA induces a variety of bioactive products including tumour necrosis factor alpha (TNF-a), interferons, interferon regulatory factors, IP-10, nitric oxide and serotonin . In the case of FAA, there is strong evidence that TNF-oc is the major mediator of the antivascular effects (Mahadevan et al, 1990) . The disappointing lack of activity of FAA in humans (Kerr and Kaye, 1989; O'Reilly et al, 1993 ) may reflect a mouse-human species difference as FAA has been shown to be considerably less effective in inducing TNF-a in human than mouse haematopoietic cells (Futami et al, 1991; Ching et al, 1994) . In contrast, DMXAA is similarly active as a TNF-oc inducer against cells of either species (Ching et al, 1994) , and unlike FAA is able to induce TNF-a synthesis by human peripheral blood leucocytes in vitro (Philpott et al, 1997) .
Although DMXAA shows dramatic activity against advanced solid tumours in mice, several studies have noted its narrow therapeutic window, with significant anti-tumour activity and cytokine induction seen only at doses close to the MTD (Baguley et al, 1993; Zwi et al, 1994a; Laws et al, 1995; Pedley et al, 1996) . This low therapeutic ratio may make it difficult to use DMXAA as a single agent in humans. The present study examines two approaches with potential for improving the therapeutic utility of DMXAA. The first is to combine DMXAA with 5-hydroxytryptamine (5-HT). 5-HT is known to inhibit tumour blood flow in mice (Peters and Chaplin, 1992) , providing preferential vasoconstriction in arterioles supplying tumour tissue (Stucker et al, 1991) . Baguley et al (1993) have shown that administration of 5-HT with a subtherapeutic dose of DMXAA (66 ,umol kg-') enhances growth inhibition of the colon 38 tumour, and similar effects have been observed with a human colon carcinoma xenograft (Pedley et al, 1996) . In the present study the potential of exogenously administered 5-HT to enhance the therapeutic activity of DMXAA is investigated using an early-passage, non-immunogenic (Moselen et al, 1995) murine breast carcinoma (MDAH-MCa-4). Three end points (tumour blood flow inhibition, necrosis and growth delay) are compared to explore further the role of blood flow inhibition in the anti-tumour activity of DMXAA and DMXAA/5-HT combinations.
The second approach examined here for improving the therapeutic ratio of DMXAA is to exploit the additional hypoxia 439 induced by blood flow inhibition to increase the metabolic activation of a bioreductive drug in the tumour. This concept was first demonstrated by the enhancement of activity of the 2-nitroimidazole alkylating agent RSU 1069 against Lewis lung tumours by 5-HT (Chaplin, 1986) . Several subsequent studies have demonstrated therapeutic synergism when bioreductive drugs are combined with TNF-ax (Edwards et al, 1991) , FAA (Sun and Brown, 1989; Edwards et al, 1991; Cliffe et al, 1994) , DMXAA (Cliffe et al, 1994; Wilson and Pruijn, 1995; Wilson et al, 1996; Vincent et al, 1997) or other antivascular treatments such as 'early' photodynamic therapy (Bremner et al, 1992) . In the present study the potential for combining DMXAA/5-HT with bioreductive drugs is explored using examples of three different bioreductive drug classes. The compounds examined are tirapazamine (TIRA), a benzotriazine-di-N-oxide (Brown, 1993) , CI-1010 (the R-enantiomer of RB 6145), which is a prodrug form of RSU 1069 (Jenkins et al, 1990; Adams and Stratford, 1994) , and SN 23816 (NSC 646394), which is a 2,4-dinitrobenzamide nitrogen mustard related to CB 1954 (Palmer et al, 1992 (Palmer et al, , 1994 Host toxicity and anti-tumour activity
Mice were C3H/HeN females, 22-25 g at the time of treatment, bred under specific pathogen-free conditions in the Animal Resources Unit, The University of Auckland. Host toxicity was assessed by determining the maximum tolerated dose (MTD), using approximately 1.3-fold dose increments. For non-tumourbearing mice the MTD was defined as the highest dose that did not cause any deaths or severe morbidity in a group of six mice, using an observation time of 28 days. In experiments with tumourbearing mice the observation time was limited by tumour regrowth, and up to one death per seven mice was considered acceptable, as occasional deaths were seen in non-drug-treated groups during tumour regrowth. Any animals that became moribund were terminated. MDAH-MCa-4 tumours (Silobrcic and Suit, 1967) were grown from stocks stored in liquid nitrogen at the fourth transplant generation. Mice were inoculated i.m. in the gastrocnemius muscle with 20 gl of a cell suspension (5 mg packed cells) prepared from fifth-generation tumours by mincing with crossed scalpels and extruding through a 200-mesh screen. Tumour sizes were determined by measuring the diameter of the tumour-bearing leg. Mice were treated when the tumour plus leg diameter reached 10 mm (0.5 g tumour), using i.p. administration (0.01 ml g-' body weight). Diameters were measured 3 days week-' after treatment, and the tumour growth delay determined as the difference between treated and control groups in the time to reach 13 mm (1.5 g tumour). The statistical significance of tumour growth inhibition was assessed by ANOVA using SAS for Windows, with Dunnett's test to evaluate P-values for differences between individual pairs of groups.
Tumour blood flow measurements Blood flow was determined using the 99mTcO4 (pertechnetate) wash-out method (Brown et al, 1988) as described previously (Cliffe et al, 1994) . Briefly, mice with 0.5-g tumours were restrained without anaesthesia and tumours were injected with 2 x 5 gt pertechnetate (1 GBq ml-' in saline) using a 30-gauge needle.
Activity in the tumour-bearing volume was recorded for six mice simultaneously, using a GE Starcam 3000 gamma camera. Pertechnetate clearance was quantified using a single exponential or weighted biexponential fit (Cliffe et al, 1994) to determine the clearance rate constant k, which was corrected for radioactive decay of 99mTc (32 x 10-s-1).
Measurement of tumour necrosis
Mice were killed and the skin overlying the tumour was carefully removed. The entire leg was fixed in 10% formalin and processed for histology. Paraffin sections (4 ,um thick) were cut, orthogonally to the long axis of the leg, from the distal, central and proximal regions of each tumour, stained with haematoxylin and eosin (H&E) and examined at 100 x magnification. An 81-square grid, providing squares corresponding to 100 x 100 tm on the section, was placed in the eyepiece, and each area was scored as predominantly viable tissue, predominantly necrotic tissue or other (which included non-tumour tissue and artefacts caused by processing). The whole area of each section was scored (approx 100 mm2 per tumour). (Figure 4) . The DMF for 5-HT, based on the DMXAA dose required for a 5-day growth delay, was 2.0. Importantly, the MTD for DMXAA in these experiments (90 ,umol kg-') was unchanged by co-administration of 5-HT.
RESULTS
British Journal of Cancer (1998) The marked inhibition of tumour blood flow by DMXAA plus 5-HT suggested that this combination might augment the antitumour activity of bioreductive drugs. The activity of TIRA against the MDAH-MCa-4 tumour was therefore investigated in combination with these blood flow inhibitors, alone and together, by varying the DMXAA dose (Figure 4) . Increased anti-tumour activity was observed when TIRA (200 tmol kg-') was administered 15 min before DMXAA, lowering the DMXAA dose required for a 5-day growth delay by a factor of 1.8. A further increase in activity was observed when 5-HT (700 gmol kg-') was added to this combination (DMF = 2.6 relative to DMXAA alone). However, host toxicity was also increased with these combinations, giving MTD values for DMXAA of 60 tmol kg-' when combined with TIRA, and 40 lmol kg-' with 5-HT plus TIRA, compared with 90 gmol kg-' for DMXAA alone. Thus, whereas adding 5-HT to DMXAA gave a therapeutic advantage, this was not the case when TIRA was included.
In separate experiments (summarized in Table 1 ) the antitumour activity and host toxicity of DMXAA/5-HT/TIRA combinations was examined by varying the dose of TIRA up to the toxic limit, using fixed doses of the blood flow inhibitors (DMXAA at 80 ,umol kg-1 and/or 5-HT at 700 .tmol kg-'). These experiments confirmed the increase in anti-tumour activity of DMXAA when combined with 5-HT. Addition of DMXAA to TIRA lowered the maximum dose of TIRA that could be tolerated from 300 to 200
,tmol kg-', but anti-tumour activity was significantly increased at the MTD. 5-HT by itself had no effect on the MTD of TIRA, and did not enhance anti-tumour activity. Addition of both 5-HT and DMXAA to TIRA enhanced host toxicity markedly, without increasing the maximal anti-tumour activity significantly over that for TIRA/DMXAA combinations without 5-HT. The increase in host toxicity of TIRA on addition of 5-HT/DMXAA was also seen in non-tumour-bearing C3H/HeN mice, with the TIRA MTD decreasing from 300 to 100 tmol kg-' when combined with DMXAA (80 tmol kg-') and 5-HT (700 jtmol kg-').
The interaction of another bioreductive drug, the 2-nitroimidazole CI-1010, with DMXAA/5-HT was examined in the same way (Table 1) . DMXAA plus Cl-l010 gave a tumour response that was clearly more than additive. In this case DMXAA did not change the MTD for the bioreductive drug, but 5-HT increased the host toxicity of CI-1010 without enhancing anti-tumour activity. 5-HT enhanced the maximum anti-tumour response to the DMXAA/CI-1010 combination; the effect of 5-HT was statistically significant in one of the two experiments, and was highly significant (P=0.001) if both experiments were pooled. As for TIRA, inclusion of 5-HT in the combination required considerable reduction of the dose of the bioreductive drug with the MTD for CI-1010 decreasing from 940 gumol kg-' without blood flow modifiers to 280 ,umol kg-' in the triple combination. The toxicity of the combination was less severe if the bioreductive drug was administered either individually or together (Table 1) . At the MTD for SN 23816, DMXAA provided a significant increase in anti-tumour activity, with an average growth delay of 11 days for this combination, and this was increased further to 26.5 days (average of two experiments) by inclusion of 5-HT. The effect of 5-HT, when combined with SN 23816 plus DMXAA, was statistically significant in both experiments (P < 0.01), whereas 5-HT by itself did not increase the activity of SN 23816. The effect of varying 5-HT dose in the combination treatment was investigated in separate experiments (Table 2 ). Host toxicity, as assessed by body weight change, was not increased by 5-HT (approximately 9% weight loss in all groups). The effect of 5-HT on anti-tumour response was statistically significant, in both experiments, only at the highest dose of 5-HT. Anti-tumour activity was diminished when administration of the bioreductive drug was delayed (Table 2) ; this decrease was statistically significant at 24 h but not at 2 h.
DISCUSSION
For each end point investigated (blood flow inhibition, necrosis and growth inhibition), the dose-response relationship for activity of DMXAA against MDAH-MCa-4 tumours was non-linear, with a threshold at about half of the MTD. This feature of DMXAA (and FAA) activity has been noted in many other studies. The requirement for doses so close to the toxic limit suggests that it will be difficult to demonstrate the activity of DMXAA in humans if its therapeutic ratio is similar to that in mice. The combination with exogenously administered 5-HT is therefore of particular interest as the anti-tumour activity of DMXAA is enhanced strongly, with little or no increase in host toxicity. The increase in anti-tumour activity of DMXAA by co-administration of 5-HT has been observed with all three tumours investigated to date, namely the mammary carcinoma MDAH-MCa-4 in this study, colon 38 tumours (Baguley et al, 1993) and LS 174T human colon adenocarcinoma xenografts (Pedley et al, 1996) . DMXAA/5HT resembles the tubulin-binding agent combretastatin A-4 in its ability to inhibit tumour blood flow at doses well below the MTD (Dark et al, 1997) , although no direct comparison has been made between these antivascular therapies. The potential of 5-HT, perhaps in combination with 5-HT3 receptor antagonists, to enhance the therapeutic ratio of DMXAA in humans thus warrants investigation. It would also be of interest to combine DMXAA with the new tumour blood flow inhibitor KB-R8498, which appears to act as a 5-HT2 receptor agonist (Sekida et al, 1997) . The mechanism by which exogenous 5-HT enhances tumour blood flow inhibition when combined with DMXAA is not known. It may be that both agents have independent effects on the tumour microvascular system. However, the observation that the 5-HT, receptor antagonist cyproheptidine inhibits colon 38 tumour necrosis by DMXAA or recombinant human TNF-a (Baguley et al, 1993) , and that the activity of TNF-ox against the 5-HT-sensitive Meth A fibrosarcoma is inhibited by 5-HT receptor antagonists (Manda et al, 1988) , led to the earlier suggestion that 5-HT might act downstream from TNF-ux in mediating DMXAA effects (Baguley et al, 1993) . If this is the case, administered 5-HT might augment this endogenous pathway. This is made less likely by recent studies indicating that systemic concentrations of 5-HT (or its oxidative metabolite 5-hydroxyindole acetic acid) are only slightly elevated after DMXAA treatment, and that this elevation is also observed following treatment with antivascular agents such as vinblastine that do not act via TNF-a . This suggests that 5-HT elevation is a consequence rather than a cause of the antivascular effects. A further, testable, hypothesis is that hypoxia induced by the early blood flow effect of exogenous 5-HT augments TNF-ox induction by DMXAA.
There is some uncertainty as to whether the anti-tumour effects of DMXAA or FAA are due exclusively to antivascular effects, or whether immunomodulatory effects make an independent contribution. In support of the latter view, growth inhibition of murine colon tumours (but not antivascular effects) is compromised by T-cell depletion (Pratesi et al, 1990; Bibby et al, 1991) although similar studies by Ching et al (1992) showed little loss of activity of either FAA or DMXAA against colon 38 tumours in nude or thymectomized mice. Further, nonvascularized tumour tissue is relatively insensitive to FAA-induced killing in mice (Finlay et al, 1988; Zwi et al, 1989 Zwi et al, , 1990 , and a correlation has been demonstrated between blood flow inhibition by FAA and growth delay using a range of non-immunogenic mouse tumours (Hill et al, 1989) . In the present study the effect of 5-HT on the anti-tumour effects of DMXAA was qualitatively similar for all three end points examined (blood flow inhibition at 4 h, necrosis at 12 h and growth delay to 3 x treatment size), although the magnitude of the dose-modifying effects (>3, 2.3 and 2.0 respectively) were not identical. The greater effect on blood flow at 4 h does not necessarily point to a non-vascular anti-tumour mechanism as greater recovery of flow is seen after the DMXAA/5-HT combination than for DMXAA alone (Figure 2 ) at a dose giving equivalent effects at 4 h. Thus, the data are broadly consistent with the view that ischaemic damage resulting from the antivascular effects of DMXAA or DMXAA/5-HT mediates the observed antitumour effect, at least in non-immunogenic tumours.
Rapid tumour regrowth despite extensive haemorrhagic necrosis has been noted in a number of studies with DMXAA or FAA (Bibby et al, 1991; Ching et al, 1992; Hill et al, 1992; Pedley et al, 1994 Pedley et al, , 1996 Figure 3 ). Using the values of V0 and V from Figure 3A , and the measured value of td (1.0 day) from Figure 3B , this gives a predicted growth delay of 6.0 days (observed 4.9 ± 0.3 days; Figure 4 ) following DMXAA alone at 80 tmol kg-' and a predicted growth delay of 5.8 days (observed 5.1 ± 1.0 days)
following DMXAA (40 gmol kg-') plus 5-HT. Thus, the necrotizing effect is sufficient to account for the observed growth delay. It is of interest that the doubling time of viable tissue after treatment of 0.5-g tumours, although not specified very accurately by the data of Figure 3B , appears to be shorter than that for control MDAH-MCa-4 tumours in the size range 0.5-1.5 g (td, 5 days), suggesting rapid repopulation of necrotic regions following DMXAA treatment. This suggests the potential for using cycleselective chemotherapy shortly after DMXAA treatment.
Previous studies have shown that DMXAA enhances the therapeutic activity of the hypoxia-activated bioreductive drugs TIRA (Cliffe et al, 1994) , CI-lOlO (Vincent et al, 1997) , SN 23816 (Cliffe et al, 1994; Wilson and Pruijn, 1995) , AQ4N (Wilson et al, 1996) and the hypoxia-selective alkylating agent melphalan (Pruijn et al, 1997) . The present study demonstrates that co-administration of TIRA, CI-1010 or SN 23816 with DMXAA provides enhanced activity against the MDAH-MCa-4 tumour. It is presumed that these interactions result primarily from induction of hypoxia after DMXAA treatment, although it has been shown with melphalan that decreased extracellular pH and entrapment of the alkylating agent as a result of falling blood flow also contribute to the increased anti-tumour activity (Pruijn et al, 1997) . Inhibition of tumour blood flow after DMXAA appears to be essentially irreversible (Figure 2 ), as noted previously (Cliffe et al, 1994) , in which case it might be expected that the cells dependent on these vessels would be fated to die as a result of ischaemic damage and that the addition of a bioreductive drug would have no further
British Journal of Cancer (1998) 78(4), [439] [440] [441] [442] [443] [444] [445] effect. The observation that bioreductive drugs increase tumour cell killing therefore argues that there is an important (treatmentlimiting) population of tumour cells that are only transiently hypoxic after DMXAA treatment and that eventually contribute to tumour regrowth. Addition of 5-HT to DMXAA-bioreductive drug combinations provides further increases in anti-tumour activity (Figure 4 and Table 1 ). The kinetics of blood flow inhibition after DMXAA/5-HT combinations (early inhibition with some reversal) is different from that after DMXAA alone (Figure 2) , and might provide more of the transient hypoxia that can be exploited by bioreductive drugs (Brown and Koong, 1991; Brown and Lemmon, 1991) . Studies of changes in blood flow (and hypoxia) at the microvascular level would assist in clarifying these issues.
Although 5-HT enhances the anti-tumour activity of DMXAA-bioreductive drug combinations, in the case of TIRA or CI-1010 there is an approximately similar increase in host toxicity so that little therapeutic advantage is obtained. There is evidence that the radioprotective effect of 5-HT in mice is due to induction of normal tissue hypoxia (Bacq, 1965) , which might also be responsible for the enhancement of bioreductive drug toxicity in the present study. However, not all bioreductive drugs suffer from this problem; the anti-tumour effect of the dinitrobenzamide mustard SN 23816 with DMXAA is enhanced to a greater extent than is host toxicity by co-administration of 5-HT, resulting in a significant therapeutic gain (Table 1) . It is not clear why the effect on host toxicity is less for SN 23816 than for the other bioreductive drugs. The oxygen dependence of TIRA cytotoxicity is quantitatively different than for RB 6145/RSU 1069 or SN 23816, with activation of the latter nitro compounds requiring much more severe hypoxia than is the case for TIRA (Koch, 1993; Wilson et al, 1994) . On this basis, both SN 23816 and CI-l010 might be expected to be less sensitive than TIRA to induction of hypoxia in normal tissues. The greater host toxicity enhancement by 5-HT for CI-1010 than for SN 23816 may indicate that different normal tissues (with different blood flow responses to 5-HT) are dose limiting for the two agents.
In conclusion, the present study demonstrates that co-administration of 5-HT with DMXAA provides marked tumour blood flow inhibition at well-tolerated doses, and that this combination is therapeutically superior to DMXAA alone as an antivascular tumour therapy in mice. Further improvement in therapeutic effect is achievable by combining DMXAA/5-HT with the bioreductive drug SN 23816, although this advantage is not obtained with the other two bioreductive drugs tested. Combination of DMXAA with 5-HT, and with appropriate bioreductive drugs, may be useful for improving the efficacy of this novel antivascular agent in clinical application.
